Intravascular catheters impregnated with antimicrobial agents: a milestone in the prevention of bloodstream infections
- PMID: 10541979
- DOI: 10.1007/s005200050297
Intravascular catheters impregnated with antimicrobial agents: a milestone in the prevention of bloodstream infections
Abstract
Vascular catheters impregnated with antimicrobial agents have been shown to decrease the risk of catheter-related colonization and bloodstream infections. Various antimicrobials and antiseptics have been used. In a recent meta-analysis of 12 studies, catheters coated with chlorhexidine and silver sulfadiazine (CH/SS) were shown to be significantly less likely to be associated with catheter-related bloodstream infections than uncoated catheters. However, these catheters were coated only on the external surface and they are associated with short antimicrobial durability (3-7 days). In addition, anaphylactic reactions to them were reported in Japan. Vascular catheters impregnated with minocycline and rifampin (M/R) were found to be highly efficacious in preventing catheter-related infections. In a recent prospective, randomized trial, the likelihood of catheter-related bloodstream infections associated with the use of M/R catheters was one-twelfth of that observed with catheters coated with CH/SS. The M/R catheters are coated on the external and internal surfaces and have an antimicrobial durability of 4 weeks. Although no resistance to either minocycline or rifampin has been seen in two trials, further studies are required to determine whether the risk of resistance outweighs the benefits derived from their use. In conclusion, antimicrobial catheters have been shown to be highly cost effective in decreasing the risk of catheter-related bloodstream infection.
Comment in
-
Vascular access investigation comes of age.Support Care Cancer. 1999 Nov;7(6):373-4. doi: 10.1007/s005200050293. Support Care Cancer. 1999. PMID: 10541975 No abstract available.
Similar articles
-
A comparison of two antimicrobial-impregnated central venous catheters. Catheter Study Group.N Engl J Med. 1999 Jan 7;340(1):1-8. doi: 10.1056/NEJM199901073400101. N Engl J Med. 1999. PMID: 9878638 Clinical Trial.
-
Which antimicrobial impregnated central venous catheter should we use? Modeling the costs and outcomes of antimicrobial catheter use.Am J Infect Control. 2003 Feb;31(1):1-8. doi: 10.1067/mic.2003.35. Am J Infect Control. 2003. PMID: 12548250
-
Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections. A randomized, double-blind trial. The Texas Medical Center Catheter Study Group.Ann Intern Med. 1997 Aug 15;127(4):267-74. doi: 10.7326/0003-4819-127-4-199708150-00002. Ann Intern Med. 1997. PMID: 9265425 Clinical Trial.
-
Antimicrobial-coated/bonded and -impregnated intravascular catheters.Ann Pharmacother. 2001 Oct;35(10):1255-63. doi: 10.1345/aph.10416. Ann Pharmacother. 2001. PMID: 11675856 Review.
-
Types of urethral catheters for management of short-term voiding problems in hospitalized adults: a short version Cochrane review.Neurourol Urodyn. 2008;27(8):738-46. doi: 10.1002/nau.20645. Neurourol Urodyn. 2008. PMID: 18951451 Review.
Cited by
-
Mechanisms of the Quorum Sensing Systems of Pseudomonas aeruginosa: Host and Bacteria.Curr Med Chem. 2024;31(35):5755-5767. doi: 10.2174/0929867331666230821110440. Curr Med Chem. 2024. PMID: 37605403 Review.
-
Rifampin combination therapy for nonmycobacterial infections.Clin Microbiol Rev. 2010 Jan;23(1):14-34. doi: 10.1128/CMR.00034-09. Clin Microbiol Rev. 2010. PMID: 20065324 Free PMC article. Review.
-
Our Experience over 20 Years: Antimicrobial Peptides against Gram Positives, Gram Negatives, and Fungi.Pharmaceutics. 2022 Dec 22;15(1):40. doi: 10.3390/pharmaceutics15010040. Pharmaceutics. 2022. PMID: 36678669 Free PMC article. Review.
-
Pseudomonas aeruginosa biofilms in disease.Microb Ecol. 2014 Jul;68(1):1-12. doi: 10.1007/s00248-013-0297-x. Epub 2013 Oct 6. Microb Ecol. 2014. PMID: 24096885 Free PMC article. Review.
-
The potential for developing new antimicrobial resistance from the use of medical devices containing chlorhexidine, minocycline, rifampicin and their combinations: a systematic review.JAC Antimicrob Resist. 2020 Feb 21;2(1):dlaa002. doi: 10.1093/jacamr/dlaa002. eCollection 2020 Mar. JAC Antimicrob Resist. 2020. PMID: 34222960 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources